Cytovia, Cellectis expand partnership to boost collaboration in China

By The Science Advisory Board staff writers

November 22, 2021 -- Cytovia Therapeutics and Cellectis have expanded their partnership on transcription activatorlike effector nuclease (TALEN) gene-edited iNK (NK cells derived from induced pluripotent stem cells, or iPSC) to allow for a broader collaboration in China.

Cellectis will continue its development of a new TALEN, which Cytovia uses to edit iPSCs, according to the two firms. The collaboration now includes a new chimeric antigen receptor target, which will be developed in China by CytoLynx Therapeutics, Cytovia's joint venture.

Cellectis will receive $20 million in Cytovia stock in addition to $805 million in development, regulatory, and sales milestones plus royalties, the two firms said.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here